Ellen Kurek

The 3-month, open-label extension trial enrolled 484 patients from multiple study sites in China, India, and Russia.

Researchers analyzed worldwide and age-related trends in the incidence of migraine between 1990 to 2019.

Researchers evaluated different doses of atogepant, fremanezumab, and erenumab for migraine prevention.

In a large-scale analysis, researchers assessed whether OSA could be a risk factor for long COVID.